Chem-/Biotech
Better adjuvants
RiboxX GmbH
RiboxX GmbH is a spin-off from the TU Dresden and has a patented platform technology for the production of double-stranded RNA. This enables the development and production of novel adjuvants for vaccines and immunotherapeutics, which RiboxX is collaborating with various companies worldwide to test. The materials can be manufactured according to GMP guidelines for use in clinical trials.
TGFS has been a shareholder in the company since 2009.
Status
Active
Segment
Early stage
Headquarter
Dresden
Website
www.riboxx.com
TGFS-Team
Dr. Matthias Kalbus
Sören Schuster